Use of biologics in the management of axial spondyloarthropathies (axSpA) has become well established in psoriatic arthritis and ankylosing spondylitis (AS). The spectrum of axSpA is becoming better understood and now includes inflammation in the absence of observable damage using radiographic techniques (nr-axSpA). In nr-axSpA, the impact on quality of life is rated as high, as the use of biologic agents is increasingly being seen as an appropriate approach in more advanced conditions such as AS. A number of manufacturers are studying the clinical benefit of NCEs and existing approved agents in this condition, resulting an a highly dynamic future market.
The RealTime Dynamix™: AS & nr-axSpA (US) report series provides a detailed and timely look at current and future trends in the AS and nr-axSpA market, and the effects of the future shifting landscape. The bi-annual releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing current key issues updated bi-annually. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the axSpA market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.